Retatrutide Reduced Weight by 18.8% in a Diabetes Trial: What Is Behind the Result

Retatrutide, an experimental obesity and diabetes drug, produced average weight loss of 18.8% at the highest dose tested in TRIUMPH-2, versus 5.1% with placebo after 80 weeks. The findings were published on September 29, 2026, in The Lancet. This is a substantial trial result, but it is still not an approved drug whose prescription availability in Israel can be inferred from the study.

The study included 1,152 adults with type 2 diabetes and overweight or obesity. Eli Lilly, the drug's developer, funded it. Understanding the result requires reading the weight loss, its calculation, and side effects together.

What was tested, and in whom

Participants were randomly assigned to four groups: retatrutide at 4, 9, or 12 mg, or placebo. The trial was double-blind, so participants and teams did not know each participant's assigned treatment. These doses describe the trial and are not instructions for use.

The main analysis found average weight loss of 11.9% in the 4 mg group, 16.8% in the 9 mg group, and 18.8% in the 12 mg group. All groups received study follow-up; the placebo group's 5.1% loss is therefore part of the comparison.

Retatrutide activates three receptors: GIP, GLP-1 and glucagon. This combined mechanism explains the research interest, but the number of receptors is not an independent measure of treatment quality or suitability for an individual.

Why the figure 20.8% also appears

The company's announcement highlighted 20.8% weight loss at the highest dose. This is not the same estimate as 18.8%: the analysis estimates efficacy had participants stayed on treatment throughout, under predefined conditions and without additional prohibited weight treatments.

The main 18.8% analysis was designed to account for treatment discontinuations and used a statistical method to fill in missing data. It too is no guaranteed prediction for everyday life. The difference between analyses illustrates why the ability to continue treatment matters alongside the strength of its effect.

Both figures are group averages. Neither means every person receiving the drug in the future will lose that proportion of weight.

Blood sugar improved, while side effects were recorded

Lilly's announcement said that in the efficacy analysis, 79% of those receiving 12 mg reached HbA1c of 6.5% or below, versus 26.3% with placebo. HbA1c reflects average blood sugar over recent months; reaching a certain value during treatment does not establish that diabetes has been cured.

Gastrointestinal effects were more common with the drug. Company data showed diarrhea in 33.6% of participants receiving 12 mg versus 13.2% with placebo, and nausea in 28% versus 8%. Put simply, each effect increased by about 20 percentage points.

The company also reported treatment discontinuation due to side effects in 7.7% at the highest dose, versus 4.9% with placebo. These figures belong beside the weight loss, not on the margins.

What the results still do not tell us

The comparison was with placebo, not Mounjaro, Ozempic, or another active drug. This trial alone therefore cannot establish that retatrutide is superior to every existing treatment. Improved weight and blood sugar alone also do not prove a reduction in heart attacks or mortality.

At the time of writing, Lilly describes retatrutide as investigational and plans a submission to the FDA in the first quarter of 2027. A planned submission date is not an approval date or a promise about price or eligibility in Israel.

For those already receiving diabetes or obesity treatment, the study provides information to discuss with a doctor, not a reason to stop treatment that works. Products sold online under the retatrutide name do not demonstrate medical approval and are not equivalent to participation in a supervised trial.

The information in this article is general and does not replace personal medical advice.